View Older Stories View More Recent Stories
-
Cosmos Health Reports Record Single-Day Direct-to-Consumer Sales in the United States Above $92,000, with $902,000 in Sales Over the Past 30 Days
-
Cosmos Health posts $54.3M in nine-month revenue, up 19%
-
Cosmos Health Reports Record Preliminary Nine-Month Revenue of $54.3 Million, Up 19% Year Over Year; Delivers Record Q3 Revenue of $17.4 Million and Reaffirms 2026 Revenue Outlook of Over $90 Million
-
Cosmos Health's Brands Reach More Than 40 Countries Across Europe, the Middle East, North America and Asia, Addressing Global Markets Estimated at Approximately $946 Billion
-
CosmoFarm hits $60M annualized revenue run-rate in Q2 2026
-
Cosmos Health's CosmoFarm Reaches Record Annualized Revenue Above $60 Million, Up 4.3x Under Cosmos Health Ownership, as Robotics and AI Build Capacity to Support Over $100 Million in Annualized Reven
-
Cosmos Health CMO pipeline tops 32.7M units with $20M implied revenue
-
Cosmos Health's Contract Manufacturing Division Surpasses $20 Million in Implied Revenue and $18 Million in Implied Gross Profit Across Its Record 32.7 Million-Unit Production Pipeline
-
Cosmos Health unit signs 5.2M-unit deal with Target Pharma
-
Cosmos Health Adds 5.2 Million Units in New Five-Year Agreements with Target Pharma; Orderbook Surges Past 32.7 Million Units, Up 31% Since June
-
Cosmos Health plans tokenized IP financing for hydrogel weight-loss device
-
Cosmos Health Moves to Tokenize CCX0722 Intellectual Property in Innovative Non-Dilutive Structure, Eyes $562 Billion Weight-Management Market
-
Cosmos Health unit secures 2.5M-unit drug manufacturing deal with Viofar
-
Cosmos Health Secures Additional 2.5 Million Units Under New Five-Year Contract Manufacturing Agreement with Viofar; Total Orderbook Surpasses 27.5 Million Units
-
Cosmos Health begins UK sales of veterinary antimicrobial C-ScrubVet
-
Cosmos Health Launches C-ScrubVet in the UK, Advancing into the $69 Billion Global Animal Health Market
-
Cosmos Health reports record revenue, retires debt early in 2026
-
Cosmos Health retires $8M convertible note a year early, buys back stock
-
Cosmos Health projects $6M in annual revenue from new olive supplement
-
Cosmos Health posts 29% revenue gain in Q2 but widens net loss
-
Cosmos Health develops AI subscription platform for consumer health products
-
Cosmos Health expands Albania distribution deal to 54,000 annual units
-
Cosmos Health signs 5-year deal to sell diabetes drug in Greece
-
Cosmos Health (COSM) Launches Subscription Model
-
Cosmos Health buys back 2.65M shares for $500K under new program
-
Cosmos Health files hydrogel weight loss patent in four markets
-
Cosmos Health antiseptic product nears $1.3M in annualized sales in Greece
-
Cosmos Health unit secures 25M-unit manufacturing orderbook
-
CosmoFarm posts record Q2 2026 revenue above $15M
-
Cosmos Health launches Korean collagen skincare line in the U.S.
-
Cosmos Health projects over $22.7M revenue from four US products
-
Cosmos Health reports $1.5m in antiseptic brand sales, eyes EU expansion
-
Cosmos Health reports record $65.3M revenue, targets $200M by 2029
-
Cosmos Health secures 5-year CERTORUN manufacturing deal worth 385,000 units
-
Cosmos Health (COSM) files $200M mixed shelf
-
Cosmos Health launches Oliv18 supplement in the US market
-
Cosmos Health expands Sky Premium Life to all 27 EU states via Skroutz
-
Cosmos Health identifies $20 million in non-core assets for potential sale
-
Cosmos Health discusses European Investment Bank financing talks
-
Cosmos Health enters animal health market with C-Scrub wash
-
Cosmos Health issues 2026-2029 guidance targeting $200m revenue by 2029
-
Cosmos Health lets 4.87 million Series B warrants expire unexercised
-
Cosmos Health Announces Expiration of 4,874,126 Series B Warrants Unexercised; ~38% of Total Outstanding Warrants
-
Cosmos Health reports record Q1 revenue of $17.9 million, up 31%
-
Cosmos Health Reports Q1 2026 Results: Revenue Up 31% to $17.9M, New Q1 Record; Total Liabilities Reduced by $4.5M; Stockholders' Equity Up 7.6%; Cash of $2.2M; Record Momentum Continues into Q2 with
-
Cosmos Health secures advisory deal with European Investment Bank
-
Cosmos Health, through its Subsidiary Cana Laboratories, Enters into an Advisory Agreement with the European Investment Bank (EIB) for the Financing of its €50M R&D Program; EIB Financing Represents
-
Cosmos Health withdraws SEC registration statement for public offering
-
Cosmos Health Announces Withdrawal of Registration Statement on Form S-1
-
Cosmos Health projects $3.2M revenue from Fort18 supplement launch
